中文产业新闻精选评分63Chinese source
依沃西单抗用于三代EGFR-TKI耐药NSCLC患者PFS达16.9个月
PFS 16.9个月丨依沃西方案破解三代EGFR-TKI耐药难题，来带长期生存获益
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
PFS 16.9个月丨依沃西方案破解三代EGFR-TKI耐药难题，来带长期生存获益
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.